avb6 integrin inhibitor + lysosomal degrader
in vitro degradation, Ph. I completed, discont.
derived from prior integrin inhibitors
J. Pharmacol. Exp. Ther., Jan. 26, 2021
GlaxoSmithKline, Stevenage, UK
“compound 1”
The GSK αvβ6 integrin inhibitor, “compound 1,” or GSK 3008348 is a previously reported IPF clinical candidate that is a picomolar binder to αvβ6 with slow dissociation kinetics. The…